Article Text

Inhibition of Renin-Angiotensin System
  1. Sharma S. Prabhakar, MD, MBA, FACP, FASN
  1. From the Department of Medicine, Texas Tech University Health Sciences Center.
  1. Received November 3, 2012.
  2. Accepted for publication November 27, 2012.
  3. Reprints: Sharma S. Prabhakar, MD, MBA, FACP, FASN, Division of Nephrology, Department of Medicine, 3601 4th St, Texas Tech University Health Sciences Center, MS 9410, Lubbock, TX 79430. E-mail: Sharma.prabhakar{at}
  4. Supported by American Heart Association–Texas affiliate, Larry and Jane Woirhaye Renal Research Foundation. Also, supported in part by a grant from the National Center for Research Resources (R13 RR023236).

Implications for Diabetes Control and Prevention


Several large-scale clinical studies have consistently demonstrated that use of inhibitors of renin-angiotensin system such as angiotensin-converting enzyme inhibitors and angiotensin receptor blockers was associated with significant reduction of new-onset diabetes in patients with insulin resistance such as primary hypertension. Such observations stimulated major investigations into the interaction of angiotensin and insulin signaling systems, which in turn led to the discovery of a cross talk at several steps between the 2 pathways. Evidence from these clinical trials and from the experimental models of insulin resistance including our findings in ZSF rat and other animal models will be discussed in this review.

Key Words
  • angiotensin inhibitors
  • insulin signaling
  • diabetes prevention

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.